XML 68 R25.htm IDEA: XBRL DOCUMENT
v3.25.3

Equity | 12 Months Ended
--- | ---
Oct. 31, 2025
Text Block [Abstract] |
Equity | Note 16: Equity Preferred and Common Shares Outstanding and Other Equity Instruments
(Canadian $ in millions, except as noted) |  | 2025 |  |  | 2024 |
|  | Number of shares |  |  | Amount |  |  | Dividends declared per share |  |  | Number of shares |  |  | Amount |  |  | Dividends declared per share |
Preferred Shares – Classified as Equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Class B – Series 31 (1) |  |  | – |  |  | $ | – |  |  |  | $        – |  |  |  | 12,000,000 |  |  | $ | 300 |  |  |  | $     0.96 |
Class B – Series 33 (2) |  |  | – |  |  |  | – |  |  |  | 0.57 |  |  |  | 8,000,000 |  |  |  | 200 |  |  |  | 0.76 |
Class B – Series 44 |  |  | 16,000,000 |  |  |  | 400 |  |  |  | 1.70 |  |  |  | 16,000,000 |  |  |  | 400 |  |  |  | 1.70 |
Class B – Series 50 |  |  | 500,000 |  |  |  | 500 |  |  |  | 73.73 |  |  |  | 500,000 |  |  |  | 500 |  |  |  | 73.73 |
Class B – Series 52 |  |  | 650,000 |  |  |  | 650 |  |  |  | 70.57 |  |  |  | 650,000 |  |  |  | 650 |  |  |  | 70.57 |
Preferred Shares – Classified as Equity |  |  |  |  |  | $ | 1,550 |  |  |  |  |  |  |  |  |  |  | $ | 2,050 |  |  |  |  |
Other Equity Instruments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
4.800% Additional Tier 1 Capital Notes (AT1 Notes) |  |  |  |  |  | $ | 658 |  |  |  |  |  |  |  |  |  |  | $ | 658 |  |  |  |  |
4.300% LRCNs, Series 1 (3) |  |  |  |  |  |  | 1,250 |  |  |  |  |  |  |  |  |  |  |  | 1,250 |  |  |  |  |
5.625% LRCNs, Series 2 |  |  |  |  |  |  | 750 |  |  |  |  |  |  |  |  |  |  |  | 750 |  |  |  |  |
7.325% LRCNs, Series 3 |  |  |  |  |  |  | 1,000 |  |  |  |  |  |  |  |  |  |  |  | 1,000 |  |  |  |  |
7.700% LRCNs, Series 4 |  |  |  |  |  |  | 1,356 |  |  |  |  |  |  |  |  |  |  |  | 1,356 |  |  |  |  |
7.300% LRCNs, Series 5 |  |  |  |  |  |  | 1,023 |  |  |  |  |  |  |  |  |  |  |  | 1,023 |  |  |  |  |
6.875% LRCNs, Series 6 (4) |  |  |  |  |  |  | 1,369 |  |  |  |  |  |  |  |  |  |  |  | – |  |  |  |  |
Other Equity Instruments |  |  |  |  |  | $ | 7,406 |  |  |  |  |  |  |  |  |  |  | $ | 6,037 |  |  |  |  |
Preferred Shares and Other Equity Instruments |  |  |  |  |  | $ | 8,956 |  |  |  |  |  |  |  |  |  |  | $ | 8,087 |  |  |  |  |
Common Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Balance at beginning of year |  |  | 729,529,876 |  |  | $ | 23,921 |  |  |  |  |  |  |  | 720,909,161 |  |  | $ | 22,941 |  |  |  |  |
Issued under the Shareholder Dividend Reinvestment and Share Purchase Plan |  |  | – |  |  |  | – |  |  |  |  |  |  |  | 7,790,724 |  |  |  | 905 |  |  |  |  |
Issued under the Stock Option Plan (Note 20) |  |  | 1,520,631 |  |  |  | 161 |  |  |  |  |  |  |  | 811,652 |  |  |  | 74 |  |  |  |  |
Treasury shares sold |  |  | 55,172 |  |  |  | 7 |  |  |  |  |  |  |  | 18,339 |  |  |  | 1 |  |  |  |  |
Purchased for cancellation |  |  | (22,200,000 | ) |  |  | (730 | ) |  |  |  |  |  |  | – |  |  |  | – |  |  |  |  |
Balance at End of Year (5) |  |  | 708,905,679 |  |  | $ | 23,359 |  |  |  | $     6.44 |  |  |  | 729,529,876 |  |  | $ | 23,921 |  |  |  | $     6.12 |
| (1) | Series 31 was redeemed and final dividends were paid on November 25, 2024.
| (2) | Series 33 was redeemed and final dividends were paid on August 25, 2025.
| (3) | 4.300% LRCNs, Series 1 was redeemed on November 12, 2025.
| (4) | On July 29, 2025, we issued LRCNs, Series 6 for US$1,000 million.
| (5) | Common shares are net of nil treasury shares as at October 31, 2025 (55,172 treasury shares as at October 31, 2024).
Preferred Share Rights and Privileges
(Canadian $, except as noted) |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Redemption amount |  |  |  | Non-cumulative dividend | (1) |  |  | Reset premium |  |  |  | Date redeemable / convertible |  |  |  | Convertible to |
Class B – Series 44 |  |  | 25.00 |  |  |  | $ 0.426000 | (2) |  |  | 2.68% |  |  |  | November 25, 2028 (3) (4) |  |  |  | Class B – Series 45 (5) (6) |
Class B – Series 50 |  |  | 1,000.00 |  |  |  | $36.865000 | (2) |  |  | 4.25% |  |  |  | November 26, 2027 (3) |  |  |  | Not convertible (6) |
Class B – Series 52 |  |  | 1,000.00 |  |  |  | $35.285000 | (2) |  |  | 4.25% |  |  |  | May 26, 2028 (3) |  |  |  | Not convertible (6) |
| (1) | Non-cumulative dividends are payable quarterly as and when declared by the Board of Directors, except for Class B – Series 50 and 52 preferred shares, which are payable semi-annually.
| (2) | The dividend rate will reset on the date redeemable and every five years thereafter at a rate equal to the 5-year Government of Canada bond yield plus the reset premium noted. If converted to a floating rate series, the rate will be set as and when declared at the 3-month Government of Canada treasury bill yield plus the reset premium.
| (3) | Redeemable on the date noted and every five years thereafter.
| (4) | Convertible on the date noted and every five years thereafter if not redeemed. If converted, the shares will become floating rate preferred shares.
| (5) | If converted, the holders have the option to convert back to the original preferred shares on subsequent redemption dates.
| (6) | The shares issued include a NVCC provision, which is necessary for the shares to qualify as regulatory capital under Basel III. Refer to the Non-Viability Contingent Capital paragraph below for details.
On August 25, 2025, we redeemed all of our outstanding 8 million Non-Cumulative 5-year Rate Reset Class B Preferred Shares, Series 33 (NVCC) for an aggregate total of $200 million. On November 25, 2024, we redeemed all of our outstanding 12 million Non-Cumulative 5-year Rate Reset Class B Preferred Shares, Series 31 (NVCC) for an aggregate total of $300 million. Other Equity Instruments On November 12, 2025, we redeemed the $1,250 million 4.300% LRCNs, Series 1 (NVCC) and the corresponding $1,250 million Preferred Shares Series 48. On July 29, 2025, we issued US$1,000 million 6.875% LRCNs, Series 6 (NVCC). As at October 31, 2025, together with the $1,250 million 4.300 % LRCNs, Series 1 (NVCC), $ 750 million 5.625% LRCNs, Series 2 (NVCC), $1,000 million 7.325% LRCNs, Series 3 (NVCC), US$1,000 million 7.700% LRCNs, Series 4 (NVCC) and US$750 million 7.300% LRCNs, Series 5 (NVCC), these LRCNs are classified as equity and form part of our Additional Tier 1 Capital. Upon the occurrence of a recourse event, the noteholders will have recourse to assets held in a consolidated trust managed by a third-party trustee. As at October 31, 2025, the trust assets comprise $1,250 million of BMO issued Non-Cumulative 5-Year Rate Reset Class B Preferred Shares, Series 48 (NVCC) (Preferred Shares Series 48), $750 million of BMO issued Non-Cumulative 5-Year Rate Reset Class B Preferred Shares, Series 49 (NVCC) (Preferred Shares Series 49), $1,000 million of BMO issued Non-Cumulative 5-Year Rate Reset Class B Preferred Shares, Series 51 (NVCC) (Preferred Shares Series 51), US$1,000 million of BMO issued Non-Cumulative 5-Year Rate Reset Class B Preferred Shares, Series 53 (NVCC) (Preferred Shares Series 53), US$750 million of BMO issued Non-Cumulative 5-Year Rate Reset Class B Preferred Shares, Series 54 (NVCC) and US$1,000 million of BMO issued Non-Cumulative 5-Year Rate Reset Class B Preferred Shares, Series 55 (NVCC) (Preferred Shares Series 55) issued concurrently with LRCNs, Series 1, Series 2, Series 3, Series 4, Series 5 and Series 6, respectively. As the Preferred Shares Series 48, Series 49, Series 51, Series 53, Series 54 and Series 55 eliminate on consolidation, they do not currently form part of our Additional Tier 1 Capital. The US$500 million 4.800% AT1 Notes (NVCC) are also classified as equity and form part of our Additional Tier 1 Capital. The AT1 Notes and LRCNs are compound financial instruments that have both equity and liability features. On the date of issuance, we assigned an insignificant value to the liability components of both types of instruments and, as a result, the full amount of proceeds has been classified as equity and forms part of our additional Tier 1 NVCC. Distributions on the AT1 Notes and LRCNs are recognized as a reduction in equity when payable. The AT1 Notes and LRCNs are subordinate to the claims of the depositors and certain other creditors in right of payment. The following table shows the details of our AT1 Notes and LRCNs as at October 31, 2025 and 2024.
(Canadian $ in millions, except as noted) |  |  |  |  |  | 2025 |  |  | 2024 |
|  | Face value |  |  | Interest rate (%) |  | Redeemable at our option |  | Convertible to |  | Total |  |  | Total |
4.800% AT1 Notes |  |  | US$500 |  |  | 6.709 (1) |  | February 2026 (2) |  | Variable number of common shares (3) |  | $ | 658 |  |  | $ | 658 |
4.300% LRCNs, Series 1 |  |  | $1,250 |  |  | 4.300 (4) |  | November 2025 (2) |  | Variable number of common shares (3) (4) |  |  | 1,250 |  |  |  | 1,250 |
5.625% LRCNs, Series 2 |  |  | $750 |  |  | 5.625 (4) |  | May 2027 (2) |  | Variable number of common shares (3) (4) |  |  | 750 |  |  |  | 750 |
7.325% LRCNs, Series 3 |  |  | $1,000 |  |  | 7.325 (4) |  | November 2027 (2) |  | Variable number of common shares (3) (4) |  |  | 1,000 |  |  |  | 1,000 |
7.700% LRCNs, Series 4 |  |  | US$1,000 |  |  | 7.700 (4) |  | May 2029 (2) |  | Variable number of common shares (3) (4) |  |  | 1,356 |  |  |  | 1,356 |
7.300% LRCNs, Series 5 |  |  | US$750 |  |  | 7.300 (4) |  | November 2034 (2) |  | Variable number of common shares (3) (4) |  |  | 1,023 |  |  |  | 1,023 |
6.875% LRCNs, Series 6 |  |  | US$1,000 |  |  | 6.875 (4) |  | November 2030 (2) |  | Variable number of common shares (3) (4) |  |  | 1,369 |  |  |  | – |
Total |  |  |  |  |  |  |  |  |  |  |  | $ | 7,406 |  |  | $ | 6,037 |
| (1) | Non-cumulative interest is payable semi-annually in arrears, at the bank’s discretion. The notes had an initial interest rate of 4.800% and reset on August 25, 2024 to 6.709%.
| (2) | The notes are redeemable at a redemption price equal to 100% of the principal amount plus any accrued and unpaid interest, in whole or in part, at our option on any interest payment date on or after the first interest reset date or following certain regulatory or tax events. The bank may, at any time, purchase the notes at any price in the open market.
| (3) | The notes issued include a NVCC provision, which is necessary for the notes to qualify as regulatory capital under Basel III. Refer to the Non-Viability Contingent Capital paragraph below for details.
| (4) | Non-deferrable interest is payable semi-annually on the LRCNs, Series 1, Series 2 and Series 3 and quarterly on the LRCNs, Series 4, Series 5 and Series 6, at the bank’s discretion. Non-payment of interest will result in a recourse event, with the noteholders’ sole remedy being their proportionate share of trust assets, which comprise our NVCC Preferred Shares Series 48 for LRCNs, Series 1, Preferred Shares Series 49 for LRCNs, Series 2, Preferred Shares Series 51 for LRCNs, Series 3, Preferred Shares Series 53 for LRCNs, Series 4, Preferred Shares Series 54 for LRCNs, Series 5 and Preferred Shares Series 55 for LRCNs, Series 6. In such an event, the delivery of the trust assets will represent the full and complete extinguishment of our obligations under the LRCNs. In circumstances under which NVCC, including the Preferred Shares Series 48, Series 49, Series 51, Series 53, Series 54 and Series 55 for LRCNs, Series 1, Series 2, Series 3, Series 4, Series 5 and Series 6, respectively, would be converted into common shares of the bank (as described below), the LRCNs would be redeemed, with the noteholders’ sole remedy being their proportionate share of trust assets, which comprise common shares of the bank received by the trust on conversion.
Authorized Share Capital We classify financial instruments that we issue as financial liabilities, equity instruments or compound instruments. Financial instruments that will be settled by a variable number of our common shares upon conversion by the holders are classified as liabilities in our Consolidated Balance Sheet. Dividends and interest payments on financial liabilities are classified as interest expense in our Consolidated Statement of Income. Financial instruments are classified as equity instruments when there is no contractual obligation to transfer cash or other financial assets. Issued instruments that are not mandatorily redeemable, or that are not convertible into a variable number of our common shares at the holder’s option, are classified as equity and presented in share capital. Dividend payments on equity instruments are recognized as a reduction in equity. Common Shares We are authorized by our shareholders to issue an unlimited number of our common shares, without par value, for unlimited consideration. Our common shares are not redeemable or convertible. Dividends are declared by our Board of Directors at their discretion. Historically, the Board of Directors has declared dividends on a quarterly basis and the amount can vary from quarter to quarter. Preferred Shares We are authorized by our shareholders to issue an unlimited number of Class A Preferred Shares and Class B Preferred Shares, without par value, in series, for unlimited consideration. Class B Preferred Shares may be issued in a foreign currency. Treasury Shares When we purchase our common shares as part of our trading business, we record the cost of those shares as a reduction in shareholders’ equity. If those shares are resold at a price higher than their cost, the premium is recorded as an increase in contributed surplus. If those shares are resold at a price below their cost, the discount is recorded as a reduction first to contributed surplus and then to retained earnings for any amount in excess of the total contributed surplus related to treasury shares. Non-Viability Contingent Capital Our preferred shares, AT1 Notes and LRCNs, by virtue of the recourse to the preferred shares held in the consolidated trusts, include a NVCC provision, which is necessary for them to qualify as regulatory capital under Basel III. As such, they are convertible into a variable number of our common shares if OSFI announces that the bank is, or is about to become, non-viable or if a federal or provincial government in Canada publicly announces that the bank has accepted, or agreed to accept, a capital injection, or equivalent support, to avoid non-viability. In such an event, each preferred share or other equity instrument is convertible into common shares pursuant to an automatic conversion formula and a conversion price based on the greater of: (i) a floor price of $5.00 and (ii) the current market price of our common shares based on the volume weighted-average trading price of our common shares on the TSX. The number of common shares issued is determined by dividing the value of the preferred share or other equity instrument issuance, including declared and unpaid dividends on such preferred share or other equity instrument issuance, by the conversion price and then applying the multiplier. Normal Course Issuer Bid On January 17, 2025, we announced a normal course issuer bid (NCIB) to purchase up to 20 million of our common shares for cancellation commencing January 22, 2025 and ending no later than January 21, 2026. On September 2, 2025, we announced the termination of this NCIB effective September 4, 2025. On September 2, 2025, we announced a new NCIB to purchase up to 30 million of our common shares for cancellation commencing September 5, 2025 and ending no later than September 4, 2026. The timing and amount of purchases under the NCIB are determined by management, based on factors such as market conditions and capital levels. During the year ended October 31, 2025, we purchased for cancellation 16.4 million common shares under the January 2025 NCIB and 5.8 million shares under the September 2025 NCIB, for a total of 22.2 million common shares , at an average price of $152.97 per share , for a total amount of $3,461 million, including tax. Share Redemption and Dividend Restrictions OSFI must approve any plan to redeem any of our preferred share issues or other equity instruments for cash. We are prohibited from declaring dividends on our preferred or common shares when we would be, as a result of paying such a dividend, in contravention of the capital adequacy, liquidity or any other regulatory directive issued under the Bank Act (Canada) . In addition, common share dividends cannot be paid unless all dividends declared and payable on our preferred shares have been paid or sufficient funds have been set aside to do so and, in certain circumstances, Class B Preferred Share dividends cannot be paid unless dividends on our Preferred Shares Series 48, Series 49, Series 51, Series 53, Series 54 and Series 55 have been paid. In addition, if the bank does not pay the interest in full on the AT1 Notes, the bank will not declare dividends on its common shares or preferred shares, or redeem, purchase or otherwise retire such shares, until the month commencing after the bank resumes full interest payments on the AT1 Notes. Currently, these limitations do not restrict the payment of dividends on common or preferred shares. Shareholder Dividend Reinvestment and Share Purchase Plan Beginning the third quarter of 2024 and until further notice, common shares under the Shareholder Dividend Reinvestment and Share Purchase Plan (DRIP) are purchased on the open market without a discount. In the first and second quarters of 2024, common shares under the DRIP were issued by the bank from treasury with a 2% discount, calculated in accordance with the terms of the DRIP. We issued 7,790,724 common shares under the DRIP in the first and second quarters of 2024. Potential Share Issuances As at October 31, 2025, we had reserved 39,864,838 common shares (39,864,838 as at October 31, 2024) for potential issuance in respect of the DRIP. We have also reserved 5,699,134 common shares ( 6,554,492 as at October 31, 2024) for the potential exercise of stock options, as further described in Note 20.

X
- References No definition available. + Details
Name: | bmo_TextBlockAbstract
Namespace Prefix: | bmo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for share capital, reserves and other equity interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 79 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration